A limited number of publications have described a reduction of spasticity associated with hereditary spastic paraplegia (HSP) after selective dorsal rhizotomy (SDR). Typically, the SDR procedure is performed on patients with spastic cerebral palsy to remove spasticity and to help these patients with ambulatory function. Whether SDR has similar effects on HSP patients, requires further investigation. Thus, we are providing a personal experience of the effects of SDR on this specific cohort of patients.
To examine the safety of SDR, changes in spasticity, and ambulatory function after SDR on patients with HSP.
The Institutional Review Board of Washington University School of Medicine approved this study (#201704003). A total of 37 children and adults received SDR for the treatment of HSP-associated spasticity between 1988 and 2021. SDR was performed through an L1 laminectomy, as we previously described in an earlier publication. The patients took part in the follow-up examination either in-person or by email. The follow-up focused on the patients’ motor functions (primarily ambulation), adverse effects of SDR, and orthopedic treatments after SDR.
Of the total 37 patients who participated in this study, 46% were female and 54% were male. The age range of when HSP was diagnosed was one month to 34 years. Six of the patients’ diagnoses were made, based on the family history of HSP in six patients and the remaining 31 patients’ diagnoses were confirmed by genetic tests. The most common genetic mutations were SPG4 and SPG3A. Of the patients with positive genetic tests, 40% had no family history of HSP. SDR was performed at the age of 2 to 45 years (mean: 14.7 years). The follow-up period ranged from 0 to 33 years (mean: 3.8 years). One patient developed a spinal fluid leak requiring surgical repair. Two patients reported mild numbness in parts of the lower limbs. Spasticity was removed in 33 patients (89%). Four patients (11%) experienced a return in spasticity. Regarding ambulatory function, 11% of patients reported a decline in function. Two patients walked independently before surgery but declined, requiring a wheelchair eight years and seven years, respectively, after surgery for each patient. In contrast, 16% saw an improvement in ambulatory function, improving from walking with a walker to walking independently. The remaining 73% of patients maintained their level of ambulation. These two groups of patients showed improvement in other motor functions and independence.
The present analysis suggests the potential role of SDR in the management of spasticity in HSP patients. We found no sign of SDR being a direct cause of deleterious effects on patients with HSP.
Hereditary spastic paraplegia (HSP) is comprised of a group of genetically and clinically heterogeneous neurodegenerative disorders . The pathological hallmark of the disorder is the presence of axon degeneration of corticospinal tracts in the distal spinal cord . Currently, there are no treatments that can prevent or reverse these pathological changes. The main clinical signs of this disorder are motor weakness and spasticity, which are predominantly observed in the lower limbs.
The current treatment of HSP is symptomatic and includes physical therapy and spasticity management. For spasticity management, anti-spasticity oral medications, Botox injections, intrathecal baclofen infusion, and selective dorsal rhizotomy (SDR) have been employed . Earlier reports described SDR reducing spasticity and improving motor functions in a small series of HSP patients [4,5]. The present report details clinical information of 37 children and adults who received SDR at our institution between 1988 and 2021.
Materials & Methods
The Institutional Review Board of Washington University School of Medicine approved this study (#201704003). We obtained consent either directly from patients or their parents or guardians. At the Center for Cerebral Palsy Spasticity, over 4,500 patients have been treated for spasticity by the means of SDR, and only 37 of those patients were diagnosed with HSP. The present study includes the total of all 37 children and adults (ages: 3-49) who received the SDR procedure for the treatment of HSP-associated spasticity between 1988 and 2021. SDR was performed through an L1 laminectomy as previously reported . About 65% of dorsal rootlets at the L1-S1 level were divided among each patient. We gathered their contact information from our database and medical records. The patients were followed up with either an in-person examination or by email.
For either follow-up method, several questions were asked about the patient. Questions about body function included level of ambulatory function (independent, walks with a walker, walks with crutches, or relies on a wheelchair) and sensory loss on any part of the lower limbs. Further questions about the perception of health, perception of SDR (whether they feel it improved the patient's overall quality of living), and negative effects of SDR were asked. Information about post-SDR orthopedic surgeries was obtained as orthopedic surgery is part of the treatment process for many patients with SDR. For those who were emailed, an initial survey was sent, then other follow-up questions were sent as needed.
Demographic information was obtained from our medical records. Demographic information included the date of birth, age at the time of this study, age at surgery, follow-up period, and gender of the patient.
Each patient’s information on their diagnosis of the specific gene mutation known to cause HSP and family history of mutation or diagnosis were found through our medical records. Patients were contacted through email or phone to confirm the genetic tests and results of HSP. The specific gene mutation was confirmed by contacting patients without a record of the specific gene mutation.
Of the 37 patients, the gender distribution was 44% female and 56% male. The age at the time of diagnosis ranged from one month to 34 years, with a majority of patients diagnosed before the age of five years. Three patients were diagnosed in adulthood. Another three patients recently received SDR and the follow-up period at the time of this study was short. These three patients are still currently being monitored. Six patients (17%) were diagnosed based on family history of HSP. These patients did not have genetic tests. The remaining 31 patients (83%) were diagnosed with positive genetic test results. The most common gene mutations were SPG4 and SPG3A. Of the 30 patients who had positive genetic tests, 40% had no family member with HSP (Table 1). Brain MRI was obtained in twenty patients. MRI was normal in 80% of the patients who had MRI. Three patients showed mild periventricular leukomalacia and one patient showed white matter heterotopia.
Regarding the age at the time of SDR, 10 patients (27%) were adults, aged between 18 and 46 years. Twenty-seven patients (73%) were children, including 14 children between 2 and 5 years of age. The patient's progression was followed for four months to 31 years. Twenty-two patients were followed for a minimum of 12 months. Fourteen patients had a follow-up period ranging from 2 to 31 years. SDR removed spasticity in 33 patients (89%). Four patients (11%) had recurrent or residual spasticity which was less severe than the spasticity before surgery. Of these four patients with recurrent or residual spasticity, three children had SPG4 or SPG10, and one adult had SPG3A genetic mutations. The time period in which the spasticity returned was 4, 6, 7, and 18 months.
Regarding ambulatory function before SDR, 21 patients (57%) walked independently, and 16 patients (43%) walked with a walker (Table 1). One child was non-ambulant but could take steps in a walker with support. The goal of surgery for this child was to improve sitting and comfort.
After SDR, 26 patients (70%) maintained their level of ambulation before and after surgery. Five patients (14%) improved their ambulation from walking with a walker to walking independently. Six patients (16%) deteriorated in their ability to walk. All of the patients who walked independently before surgery deteriorated to using a walker or cane; none required a wheelchair (Table 1). One child walked independently before and after SDR; later the child underwent a heel cord lengthening surgery at our center, which was followed by excessive foot dorsiflexion and knee crouching. The child now uses a walker and is the only child who was over-lengthened. However, we recommend orthopedic surgery to lengthen the hamstrings and heel cords for these patients. Those who improved or maintained the preoperative level of ambulation improved independence and quality of walking, sitting, and transition movements after surgery. Also, after the spasticity was reduced, patients were able to perform strengthening exercises.
Concerning sensory function after SDR, two patients experienced numbness in parts of the lower limbs. We did not examine vibratory sense in our patients before or after SDR.
Regarding orthopedic surgery, five patients received heel cord lengthening surgery before SDR. Another patient had an intrathecal baclofen pump placed. After SDR, eight patients received orthopedic surgery, i.e., heel cord and hamstring or adductor lengthening surgery.
Results of the present analysis suggest the potential role of SDR in spasticity management of HSP patients. SDR could remove or reduce HSP spasticity in all patients without deleterious effects on the clinical course of HSP. The reduction of spasticity accompanied improved ambulatory function.
The idea of performing SDR to treat HSP-related spasticity originated from the management of spasticity in cerebral palsy (CP) . In patients with CP, spasticity is only harmful and has no proven benefit to leaving untreated. It continues to reduce neurological functions and musculoskeletal systems in children and adults. Spasticity inhibits motor movements, exercise, muscle flexibility, and longitudinal muscle growth during development [8,9]. Also, it contributes to the development of muscle contracture and bony deformities [8-10]. As patients age, spasticity causes “early aging” associated with loss of mobility in adulthood . Spasticity associated with HSP may also have similar negative effects. While treating more than 4,600 CP patients with SDR since 1987, we found that SDR can remove CP spasticity permanently. After the surgery, spasticity management is unnecessary, and motor functions and quality of life improve. Moreover, patients can engage in strengthening exercises, which further improves motor functions.
Our first HSP patient underwent SDR surgery 33 years ago in 1988 (Video 1).
At that time, genetic testing for HSP was not available. The patient was born at full term. With no family history of HSP or CP, she was diagnosed with spastic diplegia at 18 months of age. The cause of her CP was unknown but we proceeded to perform SDR on her at the age of 11 years. Prior to SDR, she had spastic weakness in the lower extremities; she walked independently with knee hyperextension, and excessive lateral trunk and pelvis movement. Since SDR, she has been free of spasticity. Currently, she walks independently and uses a cane at work for added stability. She has muscle pain in her back and quadriceps, with mild hypesthesia in the quadriceps. She lives with her husband and children. Her young daughter developed toe walking, prompting a genetic test for the daughter and mother. The genetic test revealed an SPG3 mutation in both individuals.
Because of the encouraging post-SDR course observed in the first patient and availability of specific genetic tests, we began to recommend SDR for HSP patients a decade ago. Our selection criteria for surgery are 1) “Uncomplicated” HSP diagnosed by a positive genetic test or a family history of a first-degree relative who is similarly affected; we do not recommend the surgery if HSP accompanies neurologic abnormalities such as seizures, cognitive impairment, or peripheral neuropathy. 2) Neurological abnormalities limited to lower extremity spastic weakness and bladder dysfunction; those with upper extremity spastic weakness are not recommended to undergo SDR. 3) Patient’s age of 2-50 years at the time of our evaluation. A caveat is that the currently available genetic tests do not include all genes known to cause HSP, and a negative genetic test does not exclude the diagnosis of HSP . We have found that a repeat of a genetic test sometimes confirms the diagnosis. In a child born at full term who shows no abnormalities in brain magnetic resonance imaging (MRI) but has severe lateral trunk and pelvis movements when walking, HSP should be a differential diagnosis. When presented with a positive genetic test or family history, MRI is not mandatory. The MRI findings of HSP are nonspecific and are reported to include atrophy of the corpus callosum and spinal cord with a T2-signal intensity in the posterior limb of the internal capsule .
The age of onset and severity of disability varies greatly among members of the same family, in different families with the same genetic type, and between different genetic types of HSP . Such complex clinical manifestations of HSP were also present in our patients, which makes it impossible to predict the true effects of the SDR procedure on the natural course of our patient’s HSP. However, we interpret the outcome to be positive based on our findings in our patients. In all except four patients, SDR removed spasticity.
Our experience with 37patients suggests the potential role of SDR in the management of spasticity in HSP patients. SDR could remove or reduce HSP spasticity without deleterious effects on HSP. The reduction of spasticity accompanied improved ambulatory function. Other methods of spasticity management include anti-spasticity medication, Botox injection, and intrathecal baclofen infusion. The outcomes of each treatment are unknown, thus we cannot compare other treatments to SDR. Several patients reported enjoying an increase in quality of life after the SDR procedure.
- Hedera P: Hereditary Spastic Paraplegia Overview. Adam MP, Ardinger HH, Pagon RA, et al. (ed): University of Washington, Seattle, WA; 1993.
- Deluca GC, Ebers GC, Esiri MM: The extent of axonal loss in the long tracts in hereditary spastic paraplegia. Neuropathol Appl Neurobiol. 2004, 30:576-84. 10.1111/j.1365-2990.2004.00587.x
- Bellofatto M, De Michele G, Iovino A, Filla A, Santorelli FM: Management of hereditary spastic paraplegia: a systematic review of the literature. Front Neurol. 2019, 10:3. 10.3389/fneur.2019.00003
- Sharma J, Bonfield C, Steinbok P: Selective dorsal rhizotomy for hereditary spastic paraparesis in children. Childs Nerv Syst. 2016, 32:1489-94. 10.1007/s00381-016-3122-2
- Kai M, Yongjie L, Ping Z: Long-term results of selective dorsal rhizotomy for hereditary spastic paraparesis. J Clin Neurosci. 2014, 21:116-20.
- Park TS, Johnston JM: Surgical techniques of selective dorsal rhizotomy for spastic cerebral palsy. Technical note. Neurosurg Focus. 2006, 21:e7.
- Park TS, Edwards C, Liu JL, Walter DM, Dobbs MB: Beneficial effects of childhood selective dorsal rhizotomy in adulthood. Cureus. 2017, 9:e1077. 10.7759/cureus.1077
- Morrell DS, Pearson JM, Sauser DD: Progressive bone and joint abnormalities of the spine and lower extremities in cerebral palsy. Radiographics. 2002, 22:257-68. 10.1148/radiographics.22.2.g02mr19257
- Fridén J, Lieber RL: Spastic muscle cells are shorter and stiffer than normal cells. Muscle Nerve. 2003, 27:157-64. 10.1002/mus.10247
- Ziv I, Blackburn N, Rang M, Koreska J: Muscle growth in normal and spastic mice. Dev Med Child Neurol. 1984, 26:94-9. 10.1111/j.1469-8749.1984.tb04412.x
- Park TS, Uhm SY, Walter DM, Meyer NL, Dobbs MB: Functional outcome of adulthood selective dorsal rhizotomy for spastic diplegia. Cureus. 2019, 11:e5184. 10.7759/cureus.5184
- Hourani R, El-Hajj T, Barada WH, Hourani M, Yamout BI: MR imaging findings in autosomal recessive hereditary spastic paraplegia. AJNR Am J Neuroradiol. 2009, 30:936-40. 10.3174/ajnr.A1483
Selective Dorsal Rhizotomy for Treatment of Hereditary Spastic Paraplegia-Associated Spasticity in 37 Patients
Ethics Statement and Conflict of Interest Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board of Washington University School of Medicine issued approval 201704003. Criteria for approval are met per 45 CFR 46.111 and/or 21 CFR 56.111 as applicable.
Project determined to be minimal risk per 45 CFR 46.102(i) and/or 21 CFR 56.102(i) as applicable.
This approval has been electronically signed by IRB Chair or Chair Designee: Jason Hoshower, BS, CIP
10/09/20 0954. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Cite this article as:
Park T, Joh S, Walter D M, et al. (September 03, 2021) Selective Dorsal Rhizotomy for Treatment of Hereditary Spastic Paraplegia-Associated Spasticity in 37 Patients. Cureus 13(9): e17690. doi:10.7759/cureus.17690
Peer review began: June 23, 2021
Peer review concluded: August 25, 2021
Published: September 03, 2021
© Copyright 2021
Park et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.